Immunologic Research

, Volume 57, Issue 1, pp 159–165

Molecular studies and therapeutic targeting of Kaposi’s sarcoma herpesvirus (KSHV/HHV-8) oncogenesis

  • Enrique A. Mesri
  • Lucas E. Cavallin
  • Brittany M. Ashlock
  • Howard J. Leung
  • Qi Ma
  • Pascal J. Goldschmidt-Clermont
Immunology & Microbiology in Miami

DOI: 10.1007/s12026-013-8458-z

Cite this article as:
Mesri, E.A., Cavallin, L.E., Ashlock, B.M. et al. Immunol Res (2013) 57: 159. doi:10.1007/s12026-013-8458-z

Abstract

Kaposi’s sarcoma herpesvirus or human herpesvirus-8 (KSHV/HHV-8) is the etiological agent of Kaposi’s sarcoma (KS), an AIDS-defining angioproliferative neoplasm that continues to be a major global health problem and, of primary effusion lymphoma (PEL), a rare incurable B-cell lymphoma. This review describes the research from our laboratory and its collaborators to uncover molecular mechanisms of viral oncogenesis in order to develop new pathogenesis-based therapies to the KSHV-induced AIDS malignancies KS and PEL. They include the discovery of the viral angiogenic oncogene G protein-coupled receptor (vGPCR), the development of mouse models of KSHV and oxidative stress-induced KS, the identification of the role of Rac1-induced ROS in viral oncogenesis of KS and the development of novel therapeutic approaches able to target both latent and lytic oncogenic KSHV infection.

Keywords

AIDS-associated malignanciesTargeted therapiesAntiviralsHuman herpesvirus-8AngiogenesisAnimal models of cancer

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Enrique A. Mesri
    • 1
  • Lucas E. Cavallin
    • 1
  • Brittany M. Ashlock
    • 1
  • Howard J. Leung
    • 1
  • Qi Ma
    • 1
  • Pascal J. Goldschmidt-Clermont
    • 1
  1. 1.Department of Microbiology and Immunology, Graduate Program in Microbiology and Immunology, Miami Center for AIDS Research and Viral Oncology Program, Sylvester Comprehensive Cancer CenterUniversity of Miami Miller School of MedicineMiamiUSA